ACVR2B Recombinant Monoclonal Antibody

ACVR2A and ACVR2B are type II activin receptors that serve as critical gatekeepers in TGF-β superfamily signaling, mediating cellular responses to activins, myostatin, and GDF11. These serine/threonine kinase receptors play fundamental roles in processes ranging from muscle homeostasis and metabolic regulation to stem cell maintenance and embryonic development. Their involvement in diverse physiological pathways makes them compelling targets for researchers investigating signal transduction mechanisms and stem cell biology.

This recombinant monoclonal antibody, clone 7E5, offers the reproducibility and molecular definition that demanding research applications require. Generated through recombinant technology with a defined sequence, this antibody eliminates the lot-to-lot variability that can compromise longitudinal studies or multi-site collaborations. The human IgG1 format and affinity-chromatography purification ensure consistent performance across experiments.

Functional ELISA validation demonstrates robust binding to both receptor subtypes across species, with EC50 values in the low nanogram range. The antibody recognizes human ACVR2A and ACVR2B as well as their mouse orthologs, providing valuable cross-species reactivity for translational research workflows. Immunohistochemistry validation in human placenta and colon cancer tissue sections confirms reliable detection in formalin-fixed paraffin-embedded samples at 1:50–1:200 dilutions. Immunofluorescence staining has been successfully performed in SH-SY5Y neuroblastoma cells, demonstrating utility for cellular localization studies. SEC-HPLC analysis confirms greater than 95% purity, reflecting the quality expected for quantitative applications.

Whether you are investigating activin receptor signaling dynamics, exploring their roles in stem cell differentiation, or examining expression patterns in disease contexts, this antibody provides a reliable tool with documented performance across ELISA, immunohistochemistry, and immunofluorescence platforms.